1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(4-cyanophenoxy)-4-methylphenyl)urea | 1400989-31-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(4-cyanophenoxy)-4-methylphenyl)urea
• 英文别名: 1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-[3-(4-cyanophenoxy)-4-methylphenyl]urea
• CAS: 1400989-31-2
• 化学式: C₂₂H₁₅ClF₃N₃O₂
• 分子量: 445.828
• InChiKey: ZJHYNWKIDHLGTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  74.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-氯-5-氨基三氟甲苯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-(4-cyanophenoxy)-4-methylphenyl)urea
  参考文献：
  名称：

  Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity

  摘要：

  Previously, we demonstrated that the multiple kinase inhibitor sorafenib mediates the repression of phospho-STAT3 in hepatocellular carcinoma cells. In this study, we used this kinase-independent mechanism as a molecular basis to use sorafenib as scaffold to develop a novel class of SHP-1-activating agents. The proof of principle of this premise was provided by SC-1, which on replacement of N-methylpicolinamide by a phenylcyano group showed abolished kinase activity while retaining phospho-STAT3 repressive activity. Structural optimization of SC-1 led to compound 6, which repressed phospho-STAT3 through SHP-1 activation and inhibited PLC5 cell proliferation at sub-micromolar potency. In light of the pivotal role of phospho-STAT3 in promoting tumorigenesis and drug resistance, this novel SHP-1-activating agent may have therapeutic relevance in cancer therapy. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.07.023

文献信息

• [EN] AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME<br/>[FR] AGONISTES DE PROTÉINE TYROSINE PHOSPHATASE-1 CONTENANT UN DOMAINE D'HOMOLOGIE SRC-2 ET PROCÉDÉS DE TRAITEMENT L'EMPLOYANT
  申请人：UNIV NAT TAIWAN

  公开号：WO2013020014A1

  公开（公告）日：2013-02-07

  The present invention provides new compounds of formula I, II or III, which have Src homology-2 containing protein tyrosine phosphatase- 1 (SHP-1) agonist activity. Also provided are treatment methods using the compounds of formula I, II or III.

  本发明提供了式I、II或III的新化合物，这些化合物具有Src同源-2含有蛋白酪氨酸磷酸酶-1（SHP-1）激动剂活性。同时，本发明还提供了使用式I、II或III的化合物进行治疗的方法。
• COMPOUND HAVING PROTEIN TYROSINE PHOSPHATASE SHP-1 AGONIST ACTIVITY
  申请人：Chen, Kuenfeng

  公开号：EP3345894A1

  公开（公告）日：2018-07-11

  A compound having a chemical structure of formula I, wherein n is 0 or 1, X is N or C-R1, R1 is H or Cl, R2 and R3 are independently H, a halogen or an alkyl group, Ar is a substituted or unsubstituted phenylene or naphthylene group, with the substituted or unsubstituted phenylene group being A or B, and the naphthylene group being C, R4 is H, a halogen or an alkyl group, R5 is H, a halogen, an alkyl group, an alkoxyl group or a hydroxyl group, R6 is H or a hydroxyl group, and R7 is a substituted or unsubstituted aryl group. The compound has SHP-1 agonist activity, and can be used to treat cancer.

  一种具有式 I 化学结构的化合物，其中 n 为 0 或 1，X 为 N 或 C-R1，R1 为 H 或 Cl，R2 和 R3 独立地为 H、卤素或烷基，Ar 为取代或未取代的亚苯基或亚萘基、R4 是 H、卤素或烷基，R5 是 H、卤素、烷基、烷氧基或羟基，R6 是 H 或羟基，R7 是取代或未取代的芳基。该化合物具有 SHP-1 激动剂活性，可用于治疗癌症。
• Agonists of protein tyrosine phosphatase SHP-1
  申请人：Chen Kuen-Feng

  公开号：US10745346B2

  公开（公告）日：2020-08-18

  Some novel compounds are provided in this disclosure. These novel compounds have potential SHP-1 agonist activity for being used in treating cancer.

  本公开提供了一些新型化合物。这些新型化合物具有潜在的 SHP-1 激动剂活性，可用于治疗癌症。
• [EN] COMPOUND HAVING PROTEIN TYROSINE PHOSPHATASE SHP-1 AGONIST ACTIVITY<br/>[FR] COMPOSÉ PRÉSENTANT UNE ACTIVITÉ AGONISTE DE LA PROTÉINE TYROSINE PHOSPHATASE SHP-1<br/>[ZH] 具有蛋白酪氨酸磷酸酶SHP-1激动剂活性的化合物
  申请人：CHEN KUENFENG

  公开号：WO2017036405A1

  公开（公告）日：2017-03-09

  一种具有化学结构式I的化合物，其中n为0或1；X为N或C-R 1；R 1为H或Cl；R 2与R 3各自独立地为H、卤素或烷基；Ar为被取代或未被取代的亚苯基、或亚萘基，其中所述被取代或未被取代的亚苯基为A或B且所述亚萘基为C；R 4为H、卤素、或烷基；R 5为H、卤素、烷基、烷氧基、或羟基；R 6为H或羟基；以及R 7为未被取代或被取代的芳香基。所述化合物具有SHP-1激动剂活性，能够用于治疗癌症。
• AGONISTS OF SRC HOMOLOGY-2 CONTAINING PROTEIN TYROSINE PHOSPHATASE-1 AND TREATMENT METHODS USING THE SAME
  申请人：National Taiwan University

  公开号：EP2739139B1

  公开（公告）日：2019-09-25